• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Lutathera

Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology

By Pallavi Madhiraju on May 9, 2026   Medical Devices & Diagnostics  

Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology

RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.

Recent Posts

  • Why Vetter’s Saarlouis expansion matters for sterile injectable supply chains
  • How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
  • EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?
  • Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
  • Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
  • How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
  • What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics
  • Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
  • FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
  • Can BridgeBio’s Attruby narrow Pfizer’s Vyndamax lead in the ATTR-CM market?
  • Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
  • Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes